Skip to main content
Almirall S.A. logo

Almirall S.A. — Investor Relations & Filings

Ticker · ALM ISIN · ES0157097017 LEI · 95980020140005007996 MC Manufacturing
Open in API
Filings indexed 284 across all filing types
Latest filing 2021-05-21 Legal Proceedings Report
Country ES Spain
Listing MC ALM

About Almirall S.A.

http://www.almirall.com

Almirall S.A. is a global biopharmaceutical company specializing in medical dermatology. The company focuses on the research, development, manufacturing, and commercialization of proprietary medicines to address significant unmet needs in skin health. Leveraging scientific innovation, Almirall provides medical solutions designed to improve the well-being and quality of life for patients. Its operations encompass in-house research and development, strategic partnerships, and in-licensing to expand its portfolio of dermatological treatments.

Recent filings

Filing Released Lang Actions
Almirall recibe la opinión positiva del CHMP para Klisyri® (tirbanibulina), un innovador tratamiento tópico para la queratosis actínica
Legal Proceedings Report Classification · 99% confidence The document is a formal announcement dated May 21, 2021, titled 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information) from Almirall, S.A. It explicitly states that it is being issued 'en cumplimiento de lo dispuesto en la Ley del Mercado de Valores' (in compliance with the Securities Market Law). The content details a positive opinion received from the CHMP (Committee for Medicinal Products for Human Use) of the EMA regarding the regulatory approval of a drug, Klisyri®. This type of announcement, concerning regulatory milestones, clinical trial results, and expected marketing authorization timelines, is a general regulatory disclosure. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a specific management/board change, it falls best under the general category for regulatory announcements that don't fit elsewhere, which is Regulatory Filings (RNS). The document length is short (2128 chars), but it is reporting a specific event rather than announcing the publication of a separate, larger report, making RNS more appropriate than RPA.
2021-05-21 Spanish
Almirall remite presentación sobre los Resultados del primer trimestre de 2021
Investor Presentation Classification · 99% confidence The document is titled "1T 2021 Resultados financieros & Business Update" (1Q 2021 Financial Results & Business Update) and contains detailed financial figures, performance highlights for the first quarter (1T 2021), an agenda covering CEO introduction, CFO highlights, and financial situation, and tables breaking down sales by product and region for the period ending March 2021. This structure is characteristic of a comprehensive report detailing financial performance for a specific interim period (quarterly or half-yearly), but it is not the full Annual Report (10-K). The content aligns perfectly with the definition of an Interim/Quarterly Report (IR). It is not merely an announcement of a report (RPA) because the document contains the substantive financial data and analysis itself, despite its presentation format (likely a slide deck).
2021-05-10 Spanish
La Sociedad comunica el calendario del dividendo flexible
Share Issue/Capital Change Classification · 99% confidence The document is a formal announcement dated May 7, 2021, detailing the calendar and mechanics for a capital increase ('aumento de capital liberado') linked to a flexible dividend system ('sistema de dividendo flexible'). It outlines specific dates for the agreement, publication in BORME, trading periods for rights, cash payment dates, and the final listing of new shares. This content directly relates to changes in the company's capital structure and financing activities, specifically concerning shareholder remuneration via shares or cash. This aligns perfectly with the definition for 'Capital/Financing Update' (CAP). Although it mentions dividends, the core subject is the capital increase mechanism itself, not just the dividend amount (DIV) or a general regulatory filing (RNS). The document length is relatively short (3799 chars) and functions as a specific announcement of a corporate action.
2021-05-07 Spanish
Operaciones del contrato de liquidez durante el primer trimestre de 2021
Transaction in Own Shares Classification · 98% confidence The document is a regulatory filing from Almirall, S.A. ("ALM") addressed to the CNMV (Comisión Nacional del Mercado de Valores), detailing transactions conducted under a pre-existing liquidity contract (contracto de liquidez). Specifically, it reports the 'operaciones realizadas durante el noveno trimestre de vigencia de dicho contrato (desde el 1 de enero de 2021 hasta el 31 de marzo de 2021, ambos inclusive)'. This type of filing reports on the company's own transactions in its shares (purchases and sales) executed by a designated intermediary for market stabilization or liquidity purposes. This directly corresponds to the definition of 'Transaction in Own Shares' (POS), which covers share repurchase/issuance activities. It is not an Earnings Release (ER) or Interim Report (IR) as it focuses solely on liquidity operations, not comprehensive financial results. It is also not a Director's Dealing (DIRS), as it concerns the company's own transactions under a formal agreement, not personal trades by directors.
2021-04-07 Spanish
Junta General Ordinaria
AGM Information Classification · 99% confidence The document is an official announcement from Almirall, S.A. regarding the convocation of its Annual General Shareholders' Meeting ('Junta General Ordinaria de Accionistas'). It details the date (May 7, 2021), the agenda ('ORDEN DEL DIA'), and crucially, specifies that the meeting will be held 'por medios exclusivamente telemáticos' (exclusively by telematic means) due to COVID-19 restrictions. The content includes the full agenda, which covers the approval of 2020 accounts, dividend distribution, a capital increase proposal, and the re-election of directors. This document serves as the formal notice and information package for shareholders regarding the upcoming AGM, including instructions for remote attendance and voting. This aligns perfectly with the definition of materials shared during the Annual General Meeting (AGM-R), as it is the official notice and agenda for that specific event.
2021-03-23 Spanish
Almirall ha decidido no ejercer su derecho de opción para adquirir Bioniz Therapeutics Inc.
Regulatory Filings Classification · 95% confidence The document is very short (876 characters) and is titled 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information). It announces a specific corporate decision: Almirall's decision not to exercise an option to acquire Bioniz Therapeutics Inc. This is a specific corporate action announcement that does not fit neatly into the primary financial report categories (10-K, IR, ER). It is not a Director's Dealing (DIRS), Dividend (DIV), or Capital Change (CAP). Since it is a specific, material, non-standard announcement, and given the available options, the most appropriate general category for miscellaneous regulatory announcements that don't fit elsewhere is 'Regulatory Filings' (RNS). It is not an announcement *about* a report, but the report *is* the announcement itself.
2021-03-16 Spanish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.